focus -WSS

focus

author：Wikipedia 2025-09-30 02:44:43 - browse：78995

WASHINGTON, DC - NOVEMBER 27: U.S. President Joe Biden speaks about supply chain resilience during an event in the Indian Treaty Room at the Eisenhower Executive Office Building on November 27, 2023 in Washington, DC. — President Biden spoke about supply chain resilience and drug shortages. Alex Wong/Getty Images

WASHINGTON — President Biden’s new plan to curb drug shortages by boosting domestic drug production won’t expand the supply of the chemotherapies that are currently in shortage, an administration official confirmed. The limited scope surprised experts, who told STAT Biden could have included those drugs in the effort.

The 15 cancer drugs in short supply account for only a little more than 10% of the drugs on FDA’s shortage list. But chemotherapies are far more crucial than many other drugs experiencing shortages, which include injections of amino acids and multivitamins, and sterile water. Gut-wrenching stories about cancer patients being switched to less-effective drugs have caused cancer doctors to agitate for government solutions.

Biden announced last week that he plans to use the Defense Production Act to get companies to make essential medicines and their ingredients in the United States. The administration will spend $35 million to boost domestic production of key starting materials for drugs that hospitals commonly use and are prone to shortages.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Galapagos to make CAR

entertainment

WSS

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Hottest summer in 2,000 years puts focus on extreme heat, health

HHS suspends federal funding for EcoHealth Alliance

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Why don't Americans have at

Long Covid research funding gets a major boost from NIH

hotspot

focus

knowledge

Walensky prepares to leave CDC — and Congress — behind

STAT reporters are Pulitzer Prize finalists for investigative reporting

Duchenne breakthrough therapy leaves behind pioneering families

Having children helps parents live longer, especially after age 80

Medicare details structure of new drug price negotiation program

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

How to save PrEP access — and even expand it

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

hotspot

Fertility clinic egg and embryo storage is a disaster

Report cites 'urgent' need to recruit more diverse clinical trial participants

Long Covid research funding gets a major boost from NIH

Supreme Court to hear if Covid misinformation is protected speech

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Congress must protect the remaining independent doctors

explore

entertainment

focus

Wikipedia